XJZY(SZ:002332) Shang Hai Zheng Quan Bao·2025-10-29 21:46Core Viewpoint - Zhejiang Xianju Pharmaceutical Co., Ltd. has announced that its product, injection vecuronium bromide, is proposed to be selected in the 11th national centralized drug procurement, which may enhance the product's accessibility and the company's brand influence [1][2]. Group 1: Product Selection Details - The company participated in the bidding for the 11th national centralized drug procurement from October 27 to 28, 2025 [1]. - The proposed selected product is injection vecuronium bromide, which passed the national consistency evaluation for generic drug quality and efficacy in December 2023 [2]. - The final selection price, quantity, and supply provinces will be based on the data released by the procurement office [1]. Group 2: Impact on Company - The sales revenue of injection vecuronium bromide for the year 2024 and the first nine months of 2025 has been reported, indicating a potential impact on the company's financial performance [2]. - The selected product's price will decrease compared to the original sales price, which is expected to improve drug accessibility and enhance the company's brand influence if procurement contracts are signed and implemented [2].